- Poster presentation
- Open Access
Transformer (Tra2β): master regulator of myosin phosphatase alternative splicing and smooth muscle responses to NO/cGMP signaling
© Fisher et al; licensee BioMed Central Ltd. 2011
Published: 1 August 2011
Nitric oxide signaling through the cGMP kinase (cGK1α) activates Myosin Phosphatase (MP) leading to calcium de-sensitization of force production. Leucine zipper (LZ) motifs present in the C-terminus of MYPT1 and N-terminus of cGK1α are thought to be essential for the hetero-dimerization of cGK1 and MYPT1 and cGK1 activation of MP . An isoform of MYPT1 that lacks the C-terminal LZ motif is generated by the alternative splicing of a 31 nt 3’ exon (E23). We have shown that the expression of these MYPT1 isoforms is tissue-specific, developmentally regulated and modulates in disease . MYPT1 E23-/LZ+ isoform is expressed in tonic smooth muscle of the large arteries and veins while MYPT1 E23+/LZ- isoform is expressed in the phasic smooth muscle of the intestines, portal vein and small resistance arteries. There is a good though incompletely characterized correlation between the expression of MYPT1 isoforms and sensitivity to NO/cGMP-mediated relaxation, making this alternative splicing event an excellent model for the study of smooth muscle phenotypic diversity in relation to vascular function.
In a previous study we identified Transformer (Tra2β), a master regulator of splicing and sex determination in Drosophila, as a candidate tissue-specific regulator of MYPT1 E23 splicing . We now examine this question in the mouse in order to take advantage of a conditional Sfrs10 (Tra2β) knockout model . As in the rat 1) Tra2β is expressed at higher levels in phasic smooth muscle of small arteries and intestines, where E23 is spliced as compared to tonic smooth muscle of large vessels, where E23 is skipped. 2) Tra2β is developmentally up-regulated as smooth muscle acquires a phasic phenotype/E23 splicing. To test the role of Tra2β in vivo, SM22Cre and Tra2β flox mice were crossed for conditional inactivation of Tra2β in smooth muscle. The homozygous (Cre+//f/f) mice are non-viable. Heterozygous mice (Cre+//f/+) have significantly decreased levels of MYPT1 E23 inclusion in many of the phasic smooth muscle tissues.
Tra2β is necessary for tissue-specific splicing of MYPT1 E23. Tra2β may function as a master regulator of smooth muscle phenotype and responses to NO/cGMP signaling.
This work was supported by NIH grant RO1 HL-66171 to SAF and CMMC grant D7 and DFG grant Wi945/13-1 to BW.
- Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM, Mendelsohn ME: Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Ialpha. Science. 1999, 286: 1583-1587. 10.1126/science.286.5444.1583.View ArticlePubMedGoogle Scholar
- Fisher SA: Vascular smooth muscle phenotypic diversity and function. Physiol Genomics. 2010, 42A: 169-187. 10.1152/physiolgenomics.00111.2010.PubMed CentralView ArticlePubMedGoogle Scholar
- Shukla S, Fisher SA: Tra2β as a novel mediator of vascular smooth muscle diversification. Circ Res. 2008, 103: 485-492. 10.1161/CIRCRESAHA.108.178384.PubMed CentralView ArticlePubMedGoogle Scholar
- Mende Y, Jakubik M, Riessland M, Schoenen F, Rossbach K, Kleinridders A, Kohler C, Buch T, Wirth B: Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing. Hum Mol Genet. 2010, 19: 2154-2167. 10.1093/hmg/ddq094.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.